Daxor Corp
daxor.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2011 10-K, filed Mar 28, 2012. Its latest SEC filing is a 40-8F-2/A from Oct 9, 2026.
10-K for FY2011, filed Mar 28, 2012
The sections below describe the company as of the FY2011 annual report.
What Did They Do?
Sells blood-volume analyzers and single-use diagnostic kits to hospitals and imaging centers, and provides blood and semen storage services.
10-K for FY2011, filed Mar 28, 2012For the past 16 years, the Company’s major focus has been the creation and development of the BVA-100 ® Blood Volume Analyzer, an…View ↗
There is a large potential market for blood volume measurement, given that blood volume derangements are associated with a variety of…View ↗
Daxor Corporation is a medical device manufacturing company which provides additional biotechnology services, such as cryobanking and…View ↗
Who Were Their Customers?
Hospitals, surgery centers, intensive care units and radiology imaging centers use the analyzer. Daxor offers it for sale, lease or loan, and facilities borrowing it for research pay for Volumex kits used outside research.
10-K for FY2011, filed Mar 28, 2012The marketing team has made progress in identifying which facilities and departments are most able to utilize the BVA-100 in a…View ↗
How Were They Changing?
-
Mar 25, 2024
Agreed to acquire exclusive rights to Volumex, Megatope and Glofil
The agreement covers worldwide manufacturing rights for Volumex and Megatope, plus exclusive rights to Glofil, which measures kidney filtration.
Sources
8-K, filed Mar 25, 2024
On March 25, 2024 Daxor Corporation announced it has entered into a definitive agreement to acquire exclusive and worldwide rights and…View ↗
Who Did They Compete With?
Competes with American Red Cross
10-K for FY2011, filed Mar 28, 2012The blood banking industry has organizations ranging from small, limited service, providers to large full service organizations. The…View ↗
Loading...
